Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Assets (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Other Non-Current Assets for 8 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 16.72% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 16.72%, and an annual FY2024 reading of $2.1 million, up 44.85% over the prior year.
  • Other Non-Current Assets was $2.0 million for Q3 2025 at X4 Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.0 million in Q1 2025 and bottomed at $1.0 million in Q1 2023.
  • Average Other Non-Current Assets over 5 years is $1.8 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets tumbled 47.11% in 2021, then surged 101.94% in 2025.
  • Year by year, Other Non-Current Assets stood at $1.7 million in 2021, then dropped by 28.9% to $1.2 million in 2022, then increased by 17.22% to $1.4 million in 2023, then soared by 44.85% to $2.1 million in 2024, then dropped by 5.38% to $2.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for XFOR at $2.0 million in Q3 2025, $2.4 million in Q2 2025, and $3.0 million in Q1 2025.